Paper9725474
Average parameters as a trend to reduce the residual variability in bioequivalence trials.
Fagiolino P and 1 other. Eur J Drug Metab Pharmacokinet, 1998. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Average parameters as a trend to reduce the residual variability in bioequivalence trials. Papers, record 9725474. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9725474
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Average parameters as a trend to reduce the residual variability in bioequivalence trials.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Therapeutic Equivalency | Major topic |
| Analysis of Variance | |
| Clinical Trials as Topic | |
| Delayed-Action Preparations | |
| Humans | |
| Models, Statistical | |
| Saliva |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22216529 | Digoxin concentrations in serum and saliva: relationship to ECG changes and dosage in healthy volunteers. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/22216529 | PubMed |
| 2 | 7937556 | Bioequivalence: performance of several measures of rate of absorption. | Pharm Res | 1994 | https://conductscience.org/library/papers/7937556 | PubMed |
| 3 | 2200687 | Pharmacokinetic characterization of controlled-release formulations. | Eur J Drug Metab Pharmacokinet | 1990 | https://conductscience.org/library/papers/2200687 | PubMed |
| 4 | 7071071 | Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. | Pharm Acta Helv | 1982 | https://conductscience.org/library/papers/7071071 | PubMed |
| 5 | 6644568 | Bayesian approach to bioequivalence assessment: an example. | J Pharm Sci | 1983 | https://conductscience.org/library/papers/6644568 | PubMed |
| 6 | 7667204 | Without extrapolation, Cmax/AUC is an effective metric in investigations of bioequivalence. | Pharm Res | 1995 | https://conductscience.org/library/papers/7667204 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9725474
GET https://conductscience.org/api/papers/v1/9725474/authors